Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Cephalon Showcasing Treanda Use For Refractory Indolent NHL At ASH

  • News

Executive Summary

Cephalon's oncology drug Treanda is getting attention at the 2008 American Society of Hematology annual meeting, where the company is starting to showcase its use in the newest indication - refractory indolent non-Hodgkins lymphoma

You may also be interested in...



Cephalon Option To Buy Biologics Firm Ception Gets The Ball Rolling For 2009, CEO Says

Look for Cephalon to “roll up” more assets this year while the market is good, CEO Baldino says at J.P. Morgan.

Cephalon Option To Buy Biologics Firm Ception Gets The Ball Rolling For 2009, CEO Says

Look for Cephalon to “roll up” more assets this year while the market is good, CEO Baldino says at J.P. Morgan.

Cephalon Is Not Sleeping On Moving Patients From Provigil To Nuvigil

Cephalon's plans to protect its billion-dollar wakefulness franchise from the impact of generic competition to Provigil centers on switching patients to a second-generation drug, Nuvigil, with expanded indications

Table

View full table

Related Content

Pink Sheet
Tags:
Latest News

Covis, CDER Lay Out Arguments Ahead Of Makena’s Accelerated Approval Withdrawal Hearing

FDA Vaccine Advisors Put Manufacturers On Notice: New Flu Vax Licensing Requirements May Be Coming

US FDA’s ODAC Pushes Back Against ‘Leading’ Questions

Medicaid Adoption Of Medicare CED Restrictions For Alzheimer’s Drugs Weighed By MACPAC

See All
UsernamePublicRestriction

Register

PS050403

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By